Jim Cramer’s 5 rules for earnings season

Jim Cramer’s 5 rules for earnings season


CNBC’s Jim Cramer on Tuesday went over a list of do’s and don’ts for investors ahead of a busy period of earnings.

The upcoming earnings season, which kicks off this week, features quarterly updates from the nation’s largest banks, manufacturers and airlines.

Here are the five rules for investors to remember, according to Cramer:

  1. Don’t succumb to instant analysis. Investing isn’t a time-sensitive act.
  2. The first move is often the wrong move. That means investors shouldn’t make investing judgments solely based on how many companies perform compared to analysts’ consensus estimates.
  3. Don’t take your cue from the tape. In other words, investors shouldn’t buy a stock unless they’ve done the homework themselves to research the company.
  4. Read the conference calls, thoroughly. The question and answer portion is especially important since it shows if analysts are truly happy with the quarter.
  5. Make a considered decision if you buy. Weigh whether Wall Street misinterpreted the quarter – which could result in a buying opportunity.

Cramer added that a chief executive’s willingness to buy back stock after the company reports earnings is yet another sign that investors should buy the stock themselves.

Above all, investors must be cautious and measured, he said. “This is a tortoise and the hare situation, so take it slow.”

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More